Please ensure Javascript is enabled for purposes of website accessibility

Here's the Biotech Pfizer Should Consider Acquiring Next

By Keith Speights – Sep 3, 2021 at 5:52AM

Key Points

  • Pfizer plans to develop future mRNA vaccines and therapies on its own without BioNTech.
  • Acquiring a small biotech with mRNA expertise could help Pfizer achieve its goals.
  • There's one such biotech that also would give it two promising immunotherapy candidates and a solid platform for developing vaccines and immunotherapies targeting a wide range of diseases.

Motley Fool Issues Rare “All In” Buy Alert

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

This under-the-radar immunotherapy maker would bring a lot to the table for Pfizer.

Kudos to Pfizer (PFE -0.16%) for its decision to acquire Trillium Therapeutics (TRIL). The small biotech's cancer pipeline is a great fit for Pfizer. Trillium's candidates could begin contributing to Pfizer's growth in the second half of the decade, just when the big drugmaker will need a boost due to patent expirations for several of its top drugs.

The price tag of the transaction is close to $2.3 billion. That leaves Pfizer with a huge amount of cash that it could use in making more deals. There's one biotech in particular that I think Pfizer should consider acquiring next.

A person drawing a picture of a big fish about to eat a smaller fish.

Image source: Getty Images.

Going solo doesn't rule out getting some help

Pfizer and its partner BioNTech (BNTX 1.31%) achieved remarkable success with their messenger RNA (mRNA) vaccine Comirnaty (BNT162b2). The companies continue to work together on developing mRNA COVID-19 vaccines that are effective against emerging coronavirus variants. They're also collaborating on an mRNA flu vaccine program.

However, Pfizer CEO Albert Bourla revealed in a March 2021 interview with The Wall Street Journal that his company plans to move forward on its own with additional mRNA programs. Bourla said Pfizer is "the best-positioned company right now to take [mRNA technology] to the next step because of our size and our expertise."

There's no doubt that Pfizer's team did gain quite a bit of expertise with its work alongside BioNTech's scientists. Still, though, I suspect that the big pharma company wouldn't hesitate to build up that expertise even more, and gain promising mRNA technology at the same time.

That's why I think that Pfizer could be the ideal suitor for Gritstone Bio (GRTS -0.68%). It's understandable why Pfizer might be reluctant to buy BioNTech, with the German biotech's market cap near $80 billion. But Gritstone's market cap remains below $500 million. Pfizer could practically acquire the up-and-coming biotech with its spare change.

mRNA and more

Gritstone is developing its own COVID vaccine candidate that's expected to advance into early-stage clinical testing this year. But the biotech doesn't employ the ordinary mRNA approach that's used with Pfizer's Comirnaty. Gritstone's experimental vaccine uses a viral vector for the prime dose following by a self-amplifying mRNA (SAM) vector for the boost. The company believes this method could provide better protection against emerging variants than first-generation vaccines such as Comirnaty.

The small biotech brings more than just this promising mRNA technology to the table, though. Gritstone's Edge technology uses neural networks to predict which mutations will generate antigens most likely to be present on cell surfaces of viruses and tumors. The company then delivers those specific antigens using its viral prime/SAM boost vaccines.  

Gritstone already has a couple of pipeline programs in phase 2 testing. Granite is an individualized immunotherapy targeting solid tumors including metastatic microsatellite stable colorectal cancer (MSS-CRC), gastroesophageal cancer, and non-small cell lung cancer (NSCLC). Slate is an "off the shelf" immunotherapy targeting solid tumors with select KRAS mutations.

If Pfizer acquired Gritstone, the company would pick up two promising cancer immunotherapy candidates. It would gain a COVID vaccine candidate that could be ideal for battling emerging variants. The company would also add a platform that could enable it to more effectively develop a stable of new drugs targeting a variety of diseases.

Bigger targets in sight?

It's entirely possible that Pfizer could choose to buy a much larger drugmaker that would immediately boost its revenue and earnings. The company could afford to do so with its fast-growing cash stockpile.

But my view is that deals along the lines of the Trillium acquisition are a better use of Pfizer's money. The company should be able to deliver strong growth at least through 2025. Spending less now to gobble up smaller biotechs that could pay off after that point appears to be a smart game plan.

I think an acquisition of Gritstone by Pfizer could fit quite nicely with such a strategy. And it could make the big pharma stock a bigger winner over the long term.

Keith Speights owns shares of Pfizer. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Pfizer Stock Quote
Pfizer
PFE
$49.49 (-0.16%) $0.08
Gritstone bio, Inc. Stock Quote
Gritstone bio, Inc.
GRTS
$2.92 (-0.68%) $0.02
BioNTech SE Stock Quote
BioNTech SE
BNTX
$163.61 (1.31%) $2.12
Trillium Therapeutics Stock Quote
Trillium Therapeutics
TRIL

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
351%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/30/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.